HER2+ Breast Cancer | Specialty

Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study

June 2nd 2015

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer

May 31st 2015

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.

Hurvitz Looks Back and Ahead at Advances in Treating HER2-Positive Breast Cancer

May 26th 2015

In a recent interview with AJHO, Sara A. Hurvitz, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer and what the future might hold.

Dr. Pegram on Sequencing Therapies in HER2-Positive Breast Cancer

May 21st 2015

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Krop Takes Stock of Targeted Therapy Advances in HER2-Positive Breast Cancer

May 20th 2015

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.

Study Offers Solution for HER2 Resistance in Breast Cancer

May 19th 2015

By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.

Phase III Trial of Breast Cancer Vaccine Nelipepimut-S Now Fully Enrolled, Mittendorf Discusses Next Steps

April 22nd 2015

OncLive spoke with Elizabeth A. Mittendorf, MD, PhD, to learn more about the PRESENT trial and the potential impact of nelipepimut-S in breast cancer.

Dr. Mittendorf on Nelipepimut-S in Breast Cancer

April 21st 2015

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer

April 20th 2015

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

BET Bromodomain Inhibitors May Prevent Treatment Resistance in HER2-Positive Breast Cancer

April 14th 2015

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm

April 1st 2015

Patients with advanced cancers of the pancreas or prostate, or where progression to this state occurs later in the course of the illness, should have tumor or germline testing performed looking for the presence of a BRCA mutation.

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Pegram Discusses Optimal Pertuzumab Use in HER2-Positive Breast Cancer

March 24th 2015

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.

Lapatinib Falls Short Versus Trastuzumab, Adding Clarity to Frontline HER2-Positive MBC Strategy

March 20th 2015

First-line treatment with lapatinib and a taxane failed to improve progression-free survival versus trastuzumab plus a taxane in patients with HER2-positive metastatic breast cancer in the MA.31 trial.

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer

March 11th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast Cancer

February 28th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, goes over some of the challenges surrounding neoadjuvant treatment for HER2-positive breast cancer patients.

Driver Mutations Remain Prognostic But Not Predictive in Breast Cancer

February 27th 2015

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

Future Treatments for Triple-Negative Breast Cancer

February 25th 2015

Chemotherapeutics for Triple-Negative Breast Cancer

February 25th 2015

Standard Therapies for Triple-Negative Breast Cancer

February 25th 2015